Mirati Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRTX research report →
Companywww.mirati.com
Mirati Therapeutics, Inc. , a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.
- CEO
- Charles M. Baum
- IPO
- 2013
- Employees
- 587
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $4.12B
- P/E
- -4.46
- P/S
- 331.11
- P/B
- 3.31
- EV/EBITDA
- -5.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 95.18%
- Op Margin
- -6107.98%
- Net Margin
- -5957.44%
- ROE
- -61.91%
- ROIC
- -72.27%
Growth & Income
- Revenue
- $12.44M · -82.75%
- Net Income
- $-740,867,000 · -27.34%
- EPS
- $-13.18 · -17.57%
- Op Income
- $-759,589,000
- FCF YoY
- -44.36%
Performance & Tape
- 52W High
- $64.41
- 52W Low
- $27.30
- 50D MA
- $57.69
- 200D MA
- $45.48
- Beta
- 0.77
- Avg Volume
- 1.78M
Get TickerSpark's AI analysis on MRTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 23, 24 | Boxer Capital, LLC | sell | 1,413,475 |
| Jan 23, 24 | Boxer Capital, LLC | sell | 30,518 |
| Jan 23, 24 | Sharp Shalini | sell | 4,162 |
| Jan 23, 24 | Sharp Shalini | sell | 5,252 |
| Jan 23, 24 | Sharp Shalini | sell | 7,520 |
| Jan 23, 24 | Sharp Shalini | sell | 6,808 |
| Jan 23, 24 | Cherrington Julie M | sell | 4,444 |
| Jan 23, 24 | Cherrington Julie M | sell | 6,808 |
| Jan 23, 24 | Cherrington Julie M | sell | 7,520 |
| Jan 23, 24 | Davis Aaron I. | sell | 43,073 |
Our MRTX Coverage
We haven't published any research on MRTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRTX Report →